Why this matters (and dont underestimate it): ~20% weight loss in non-diabetic obesity (REDEFINE-1) 1416% weight loss in T2D (REDEFINE-2) Dual mechanism = appetite suppression + satiety reinforcement Designed for long-term maintenance, not just short-term loss Potentially better GI tolerability with flexible titration This isnt another GLP-1. Its a clear signal that amylin is emerging as a serious second pillar in next-gen obesity care
GLP-1 is a hormone released by the small intestine after eating, in response to carbohydrate and fat
Consequently, PH will result in swifter muscle recovery and remodeling following exercise/ muscle injury [186, 188]
When to Consult a Healthcare Provider Before starting a GLP-1 such as semaglutide (Wegovy), tirzepatide (Zepbound), or any other medication, consult with your healthcare provider to make sure its safe for you, especially if you have any underlying health conditions or are taking certain medications
BPC-157 protects gut and digestive health by strengthening the mucosal lining, reducing epithelial inflammation, and restoring blood flow to damaged digestive tissue